{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T21:24:33Z","timestamp":1767734673781,"version":"3.48.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T00:00:00Z","timestamp":1501027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.bbrc.2017.07.148","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T23:15:51Z","timestamp":1501110951000},"page":"656-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment with a programmed cell death-1-specific antibody has little effect on afatinib- and naphthalene-induced acute pneumonitis in mice"],"prefix":"10.1016","volume":"491","author":[{"given":"Naoki","family":"Hamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toyoshi","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saiko","family":"Ogata-Suetsugu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Mikumo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Arimura-Omori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2017.07.148_bib1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial","volume":"13","author":"Yang","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2017.07.148_bib2","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","article-title":"Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2017.07.148_bib3","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4082\/kjfm.2016.37.6.351","article-title":"Afatinib-induced acute fatal pneumonitis in metastatic lung adenocarcinoma","volume":"37","author":"Yoo","year":"2016","journal-title":"Korean J. Fam. Med."},{"key":"10.1016\/j.bbrc.2017.07.148_bib4","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.jtho.2016.10.011","article-title":"Afatinib-induced severe interstitial lung disease successfully treated with high-dose corticosteroid therapy: a case report","volume":"12","author":"Fujita","year":"2017","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.bbrc.2017.07.148_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2017.07.148_bib6","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","article-title":"PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course","author":"Nishino","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2017.07.148_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2017.07.148_bib8","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor\u2013related pneumonitis in patients with advanced cancer","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbrc.2017.07.148_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s10637-016-0389-9","article-title":"Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody","author":"Mamesaya","year":"2017","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bbrc.2017.07.148_bib10","article-title":"High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy","author":"Kotake","year":"2016","journal-title":"Ann. Oncol."},{"year":"2016","series-title":"Pharmaceuticals and Medical Devices Safety Information No. 336 September 2016","key":"10.1016\/j.bbrc.2017.07.148_bib11"},{"key":"10.1016\/j.bbrc.2017.07.148_bib12","doi-asserted-by":"crossref","first-page":"L529","DOI":"10.1152\/ajplung.00082.2006","article-title":"Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis","volume":"292","author":"Gazdhar","year":"2007","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.bbrc.2017.07.148_bib13","first-page":"L800","article-title":"Cellular response in naphthalene-induced Clara cell injury and bronchiolar epithelial repair in mice","volume":"269","author":"Van Winkle","year":"1995","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.bbrc.2017.07.148_bib14","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1164\/rccm.201002-0188OC","article-title":"EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium","volume":"183","author":"Harada","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bbrc.2017.07.148_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbrc.2017.03.031","article-title":"Neutrophil elastase inhibitor sivelestat ameliorates gefitinib-naphthalene-induced acute pneumonitis in mice","volume":"486","author":"Mikumo","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2017.07.148_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/aps.2016.161","article-title":"Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody","author":"Fu","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.bbrc.2017.07.148_bib17","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.4049\/jimmunol.0903478","article-title":"Premature terminal exhaustion of friend virus-specific effector CD8+ T cells by rapid induction of multiple inhibitory receptors","volume":"184","author":"Takamura","year":"2010","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.bbrc.2017.07.148_bib18","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.4049\/jimmunol.175.3.1586","article-title":"Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production","volume":"175","author":"Yamazaki","year":"2005","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.bbrc.2017.07.148_bib19","doi-asserted-by":"crossref","first-page":"L642","DOI":"10.1152\/ajplung.00021.2013","article-title":"Club cell secretory protein improves survival in a murine obliterative bronchiolitis model","volume":"305","author":"Wendt","year":"2013","journal-title":"AJP Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.bbrc.2017.07.148_bib20","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.pupt.2011.08.001","article-title":"In\u00a0vivo efficacy of KRP-109, a novel elastase inhibitor, in a murine model of severe pneumococcal pneumonia","volume":"24","author":"Yamada","year":"2011","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2017.07.148_bib21","unstructured":"Lee et Downey, Leukocyte Elastase - Physiological Functions and Role in Acute Lung Injury, 3 (2001). http:\/\/www.atsjournals.org.ez.statsbiblioteket.dk:2048\/doi\/pdf\/10.1164\/ajrccm.164.5.2103040."},{"key":"10.1016\/j.bbrc.2017.07.148_bib22","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bbrc.2017.07.148_bib23","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/S1556-0864(16)30246-5","article-title":"136O: osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: results from the TATTON phase Ib trial","volume":"11","author":"Ahn","year":"2016","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.bbrc.2017.07.148_bib24","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S1556-0864(16)30171-X","article-title":"57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): a phase I expansion in TKI-na\u00efve patients (pts) with EGFR mutant NSCLC","volume":"11","author":"Gibbons","year":"2016","journal-title":"J.\u00a0Thorac. Oncol."},{"key":"10.1016\/j.bbrc.2017.07.148_bib25","first-page":"S34","article-title":"Safety and response with nivolumab (Anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC)","volume":"90","author":"Schuler","year":"2013","journal-title":"Radiat. Oncol. Biol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X17315061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X17315061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T21:23:13Z","timestamp":1767734593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X17315061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0006291X17315061"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2017.07.148","relation":{},"ISSN":["0006-291X"],"issn-type":[{"type":"print","value":"0006-291X"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment with a programmed cell death-1-specific antibody has little effect on afatinib- and naphthalene-induced acute pneumonitis in mice","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2017.07.148","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}